BACTERIAL VAGINOSIS AND DESQUAMATIVE INFLAMMATORY VAGINITIS: CHOICE OF AN EFFECTIVE THERAPY METHOD. REVIEW
2022 жыл | Шығарылым: 4 | Беттер: 216-223
ТРЕВОЖНО-ДЕПРЕССИВНЫЕ РАССТРОЙСТВА ПРИ ХРОНИЧЕСКИХ ВИРУСНЫХ ГЕПАТИТАХ. ОБЗОР ЛИТЕРАТУРЫ
2022 жыл | Шығарылым: 4 | Беттер: 206-215
ВОЗМОЖНОСТИ ОПТИМИЗАЦИИ ТАКТИКИ ПЕРИОПЕРАЦИОННОГО ВЕДЕНИЯ ПАЦИЕНТОВ С ХРОНИЧЕСКИМ ГЕМОРРОЕМ НА ОСНОВЕ ПРОГРАММ УСКОРЕННОГО ВОССТАНОВЛЕНИЯ. ОБЗОР ЛИТЕРАТУРЫ
2022 жыл | Шығарылым: 4 | Беттер: 196-205
MODERN APPROACHES FOR DIAGNOSTICS AND TREATMENT OF URETHRAL STRICTURES AFTER ADENOMECTOMY: REVIEW
2022 жыл | Шығарылым: 4 | Беттер: 188-195
ETIOPATHOGENESIS AND SURGICAL TREATMENT OF BILIARY PANCREATITIS. REVIEW
2022 жыл | Шығарылым: 4 | Беттер: 176-187
ASSESSMENT OF THE EFFECTIVENESS OF MEASURES TO PREVENT COMPLICATIONS OF SURGICAL TREATMENT IN PATIENTS WITH OCCLUSION OF THE AORTO-ILIAC SEGMENT
2025 жыл | Шығарылым: 5 | Беттер: 70-77
EVALUATION OF QUALITY OF LIFE IN PATIENTS AFTER SURGICAL TREATMENT OF POSTOPERATIVE VENTRAL HERNIAS
2025 жыл | Шығарылым: 5 | Беттер: 78-86
ACID–BASE BALANCE AND GAS EXCHANGE IN PATIENTS WITH DRUG-RESISTANT EPILEPSY DURING THE PERIOPERATIVE PERIOD: THE ROLE OF CLINICAL CHARACTERISTICS AND THERAPY
2025 жыл | Шығарылым: 5 | Беттер: 87-94
COMPARATIVE ASSESSMENT OF CANDIDA SPP. SUSCEPTIBILITY AND RESISTANCE TO ANTIFUNGAL AGENTS BY BIOLOGICAL MATERIAL TYPE
2025 жыл | Шығарылым: 5 | Беттер: 95-102
ASSESSMENT OF QUALITY OF LIFE IN HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY USING THE STANDARDIZED SF-36 INSTRUMENT
2025 жыл | Шығарылым: 5 | Беттер: 103-111
USING OF ATORIS AT FEMALES WITH ARTERIAL HYPERTENSION AND HYPERLIPIDEMIA
So, medicine Atoris is may be used as high effective lipid lowering drug for secondary prophylaxis of cardiovascular compli-cations at females with high risk of ischemic heart disease.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 40-42
ARTERIAL HYPERTENSION AT OLD AGE PATIENTS
Problem of arterial hypertension at old age patients is connected with it’s wide spreading and tendency to aging of popu-lation. In old age there are different risk factors and accompanying diseases, which permit to say about that group of patients are in high or very high risk of cardiovascular complications not depending on degree of increasing of blood pressure.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 38-40
DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (CHF)
This lecture consist of actuality, definition, main etiological factors of chronic heart failure and diagnostic criteria. And there is medicamentous therapy and principles of surgical and electrophysiological methods of treatment of CHF in this lecture.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 32-37
CALCIUM CHANNELS BLOCKERS - A ROLE IN MODERN THERAPY OF CARDIOVASCULAR DISEASES: IN FOCUS – DILTIAZEM
Calcium channels blockers – group of the drugs which basic property is ability to brake a calcium current inside of smooth muscle cells through the special channels named “slow calcium channels”. Diltiazem Lannacher renders cardioprotective action with antioxidative effect, angioprotective action, antiagregant action, antiatherogenous action, nephroprotective action, cerebroprotective action.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 24-34
DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AT TREATMENT OF ARTERIAL HYPERTENSION: LERKAMEN
Arterial hypertension (AH) is independent risk factor of myocardial infarction, brain stroke, chronic heart failure (CHF) and hypertensive nephropathy, death from cardiovascular diseases.
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 18-24